Clinical Trials
-
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
3/28/2024
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.
-
CRI's Response to NIH Cuts with Alicia Zhou, Ph.D.
4/22/2025
In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research.
-
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino
9/11/2024
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.
-
Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry
6/15/2026
For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues.
-
Pioneering Next-Gen TCR Therapies In Solid Tumors With Neogene Therapeutics' Carsten Linnemann, Ph.D.
10/9/2024
Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers.
-
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts
8/29/2024
Cell & Gene: The Podcast Host, Erin Harris, welcomes Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, for an in-depth interview about existing issues with current CAR T approaches, "auto versus allo," and why allogeneic is the path forward. They also discuss how and why allogeneic therapies are truly scalable.
-
Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki
12/22/2025
In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA).
-
Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach
6/30/2026
Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach, to explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma.
-
Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.
4/22/2026
On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host Erin Harris about how targeting LSD1 is unlocking new treatment approaches across oncology, CNS disorders, and sickle cell disease, with promising early clinical data and a strategy grounded in precision epigenetics.
-
Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous
2/24/2026
In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials.